Clinical Trial

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Enrolling by Invitation Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-02; most recent amendment 2026-03-19.
Trial Details
NCT Number NCT06763965
Lead Sponsor Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Conditions Recurrent High-grade Glioma
Enrollment 30 participants
Start Date 2024-11-26
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-23